Posted by Michael Wonder on 18 Jun 2024
Grifols’ Biotest receives FDA approval for innovative Yimmugo immunoglobulin to treat primary immunodeficiencies
17 June 2024 - Launching Yimmugo in the US will over time significantly add to Grifols Group sales and underpins its future growth strategy
Grifols has received approval from the US FDA for Yimmugo, an innovative intravenous immunoglobulin therapeutic, to treat primary immunodeficiencies.
